Type 1 Diabetes

For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …

Biotin supplements have become increasingly popular among people living with diabetes. Many individuals take them to support healthy hair and nails, while others use high-dose formulations in hopes of easing neuropathy symptoms. An often-overlooked concern is biotin interference with laboratory tests used in diabetes care. Although biotin itself does not …

For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …

Population-based screening for type 1 diabetes is entering a new era. While autoantibody testing remains the gold standard for identifying individuals at high risk, researchers are increasingly investigating whether type 1 diabetes genetic screening could identify susceptible people even earlier. Advances in genomic science now make it possible to estimate …

For more than a century, insulin has been the foundation of type 1 diabetes care. However, even the best insulin pumps, continuous glucose monitors, and automated insulin delivery systems still cannot fully replace the body’s lost beta cells. That is why interest in stem cell islet transplant diabetes research continues …

For decades, treatment after a type 1 diabetes diagnosis focused almost entirely on insulin replacement and blood glucose management. While advances in technology have improved care, clinicians have had few ways to address the autoimmune process driving beta-cell loss. That is beginning to change. With the FDA’s expansion of teplizumab-mzwv …

As diabetes technology continues to evolve, clinicians are increasingly faced with an important question: should patients still be using flash continuous glucose monitoring (CGM), or is it time to switch to real-time CGM? While flash CGM systems have significantly improved glucose monitoring and patient engagement over traditional fingerstick testing, real-time …

As population-based screening for type 1 diabetes (T1D) becomes more common, clinicians increasingly encounter positive islet autoantibody results in children and adults who have no symptoms. However, not all positive screening results carry the same clinical significance. A single positive autoantibody may indicate elevated risk, yet the specific antibody detected …

For many people living with diabetes, gaining access to an automated insulin delivery (AID) system can be life-changing. These technologies help improve glycemic outcomes, reduce hypoglycemia risk, and ease the daily burden of diabetes management. Yet despite their proven benefits, many patients continue to face lengthy delays before gaining access. …

For years, hospital admission often meant disconnecting patients from their personal diabetes devices. Continuous glucose monitors (CGMs) and insulin pumps were frequently removed, even when patients had used them successfully at home. However, the 2026 American Diabetes Association (ADA) Standards of Care introduce a significant shift in how hospitals approach …